ClinicalTrials.Veeva

Menu
Y

Yashoda Hospital | Clinical Research Department

Research site

Site insights

Top conditions

Top treatments

Dexamethasone
ABX464
Carfilzomib
Milvexian
Ozanimod
Lyrica
Hydroxyurea
Methylprednisolone
Cytarabine
Diclofenac Sodium

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Shailaja Boya

Verified by this site

Active trials

16 of 34 total trials

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Enrolling
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Drug: Physician's Choice medications
Drug: Pacritinib

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Active, not recruiting
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaci...

Active, not recruiting
Neoplasm Metastasis
Breast Neoplasms
Drug: Abemaciclib
Drug: Fulvestrant

The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or a...

Enrolling
Neutropenia
Drug: Placebo
Drug: Mavorixafor

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-al...

Enrolling
Dyslipidemias
Obesity
Drug: Saroglitazar
Locations recently updated

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Active, not recruiting
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS...

Active, not recruiting
Acute Myeloid Leukemia
Other: Observation
Other: Montanide

The study aims to evaluate the safety and efficacy of the Supernova stent retriever device, developed by Gravity Medical Technology, for treating acu...

Enrolling
Ischemic Stroke
Stroke
Device: Supernova revascularization device

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination o...

Active, not recruiting
Sickle Cell Disease
Drug: HU - Hydroxyurea
Drug: Placebo

To characterize safety associated with the use of Kyprolis under the locally approved label.

Active, not recruiting
Relapsed Refractory Multiple Myeloma
Drug: Drug: Carfilzomib + Dexamethasone
Drug: Drug: Carfilzomib + Lenalidomide + Dexamethasone

Trial sponsors

Roche logo
A
Janssen (J&J Innovative Medicine) logo
Novo Nordisk logo
Pfizer logo
Amgen logo
Bayer logo
Biocad logo
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems